AccuRad Technology

AccuRad is a clinical-stage biotechnology company focused on the development of innovative radiopharmaceuticals for the treatment and diagnosis of cancer. Based in Suzhou, China, the company employs a theranostic strategy to create targeted radionuclide therapies that combine precision imaging with potent therapeutic isotopes. Its lead pipeline programs include ARC-001, targeting somatostatin receptors for neuroendocrine tumors, and ARC-002, targeting prostate-specific membrane antigen for prostate cancer. AccuRad operates a fully integrated platform encompassing ligand design, radiochemical synthesis, and GMP-compliant manufacturing to accelerate the delivery of next-generation oncology treatments. The company is backed by prominent venture capital firms and aims to establish a leading position in the rapidly growing global radiopharmaceutical market.